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Results:	 Under	 the	 40%	 linked-	to-	care	 scenario,	 viraemic	 burden	would	 decline	
(60%);	however,	eligible	patients	to	treat	will	be	depleted	by	2025.	Increased	case	
finding	 through	 a	 targeted	 screening	 strategy	 in	 1948-	1978	birth	 cohorts	 could	
supplement	the	pool	of	diagnosed	patients	by	finding	75%	of	F0-	F3	cases.	Under	
the	 60%	 linked-	to-	care	 scenario,	 viraemic	 infections	 would	 decline	 by	 70%	 by	
2030	but	the	patients	eligible	for	treatment	will	run	out	by	2028.	If	treatment	is	to	
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cancer	 if	 left	 untreated.2,3	However,	 the	 development	 of	 direct-	
acting	 antiviral	 (DAA)	 therapy	 has	 revolutionized	 the	 approach	
to	 treatment	 and	 reinvigorated	public	health	 initiatives	 aimed	at	
identifying	 patients	 with	 CHC.	 Galvanized	 by	 these	 results,	 the	
World	 Health	 Organization	 (WHO)	 foresees	 the	 elimination	 of	
HCV	infection	by	2030	through	achieving	the	Global	Health	Sector	




essary	 in	 the	 general	 population	 of	 high	 endemic	 countries	 for	
achieving	 these	goals.	Given	 that	 the	use	of	DAAs	 regardless	of	
fibrosis	stage	is	cost-	effective,7	it	is	crucial	that	health	policies	ex-
pand	treatment	access	for	all	HCV-	infected	 individuals.	The	goal	
of	 this	study	was	 to	use	a	new	modelling	approach,	grounded	 in	
real-	life	cohort	data	of	diagnosed	and	treated	patients,	to	compare	
different	 linkage	 to	 care	 scenarios	 to	 the	 overall	 HCV-	infected	

















treatment	 access	 restrictions	 on	 the	 basis	 of	 healthcare	 system	
reimbursement	 criteria.8	 PITER	 aims	 to	 evaluate	 the	 expected	
impact	of	DAAs	on	 the	natural	 course	of	hepatitis	 infection	and	
on	long-	term	morbidity	and	mortality	in	a	real-	life	setting	in	Italy.	
The	 PITER	 inclusion	 criteria	 are:	 all	 HCV-	infected	 patients	 (any	
stage,	 any	 genotype,	 including	 HBV,	 HDV,	 or	 HIV	 co-	infection)	
at	least	18	years	of	age	consecutively	referred	to	outpatient	clin-
ics	of	 the	participating	 clinical	 centres	during	enrolment	phases,	
who	are	untreated	at	the	time	of	enrolment.	The	mean	age	of	en-
rolled	 patients	 is	 61	 (range	 18-	94)	 years	 of	 age	 and	 the	 ratio	 of	
males	 to	 female	 is	 1/1.2	 (55%	male).8	 The	 older	 age	 of	 patients	
enrolled	in	PITER	represents	the	cohort	effect	of	HCV	infection	in	
Italy.	Of	patients	enrolled	in	the	PITER	cohort	in	2016,	52%	were	









2017,	 treatment	was	 expanded	 to	 all	 patients	 independent	 of	 fi-
brosis	score.9
2.1.3 | Italy Polaris and PITER adjusted models
For	 this	 analysis,	 two	 separate	 models	 were	 constructed.	 First,	 a	





tion	was	back-	calculated	 to	match	 the	modelled	prevalence	by	 sex	
and	age	group	in	2015	to	reported	estimates11	(Section	1	in	Appendix	
S1).	The	reported	number	of	annual	treated	patients	as	tracked	in	the	
AIFA	Monitoring	Registry	 for	DAAs9	was	 allocated	 to	 the	 age	 and	
liver	 disease	 stage	 of	 the	 eligible	 HCV-	infected	 population	 by	 the	
relative	 size	 of	 population	 in	 each	 treatment-	eligible	 disease	 stage	
Key Points









case	 finding	 in	 individuals	born	between	1948-1978	 is	
necessary	to	achieve	the	WHO	elimination	goals.	If	the	
treatment	rate	is	sustained	until	2028,	screening	strate-
gies	 focusing	 on	 individuals	 born	 between	 1958-1978	
are	warranted.
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(Table	1).	The	number	of	annual	treatments	initiated	within	each	dis-
ease	stage	was	uniformly	distributed	across	treatment-	eligible	ages.















Represents	 the	2016	 standard	of	 care	 in	 Italy	 (treatment	of	 pa-
tients	with	fibrosis	stage	≥F3)	maintaining	the	same	fibrosis	stage,	
Italy specific parameters in 
model Year Value (Range) Source
Total	viraemic	population 2015 849	000	(371	000-	1	240	000) 13
Viraemic	prevalence 2015 1.39%	(0.6%-	2.00%) 13
Viraemic	diagnosed	population 2015 357	000	(255	000-	510	000) Expert	input
Annual	newly	linked	to	care	for	
treatmenta
2013 30 400 Expert	input





A 2015 2016 2017 2018 2019 2020+
Annually	treated
Base	2016 31 000 33 700 29 500 25 300 21 100 16 900
PITER	(40%,	60%,	80%) — 33 700 33 700 33 700 33 700 33 700
Tx-	eligible	stages
Base	2016 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3
PITER	(40%,	60%,	80%) ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx-	eligible	ages
Base	2016 15-	64 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
PITER	(40%,	60%,	80%) 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
SVR
Base	2016 93% 93% 93% 93% 93% 93%
PITER	(40%,	60%,	80%) — 93% 95% 98% 98% 98%
B 2015 2016 2017 2020 2022 2025+
Annually	treated
WHO	targets 31 000 33 700 33 700 35 700 36 700 38 000
Newly	linked	to	carea
WHO	targets 30 400 30 400 30 400 33 400 35 400 36 400
Tx-	eligible	stages
WHO	targets ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx-	eligible	ages
WHO	targets 15-	64 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
SVR
WHO	targets 93% 93% 95% 95% 98% 98%
SVR,	sustained	virological	response;	Tx,	treatment;	WHO,	World	Health	Organization.
aAnnual	Newly	Linked	to	Care	for	Treatment	encompasses	those	newly	diagnosed	each	year.
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treatment	age	and	SVR	rate	assumptions	through	2030.	In	2016,	
30	400	patients	were	considered	 to	be	newly	 linked-	to-	care	 for	
treatment	 annually	 and	 33	700	 patients	were	 treated	 that	 year.	
As	no	screening	strategy	is	in	place	in	Italy,	the	number	of	treated	
patients	 was	 expected	 to	 decrease	 by	 half	 by	 2020	 due	 to	 the	
depleting	pool	of	eligible	patients	to	treat.12
WHO Targets
The	WHO	 Targets	 scenario	 identifies	 the	 expansion	 of	 diagnosis	














care.13	 Since	 the	 exact	 number	 of	 patients	 linked-	to-	care	 remains	
unknown,	 the	 same	 scenario	was	 then	 run	 under	 the	 assumption	





To	 assess	 the	 effect	 of	 uncertainties	 in	 model	 inputs,	 we	 used	
















the	 relatively	 large	number	of	patients	 treated	 in	 Italy,	 total	 infec-
tions	are	expected	to	decline	to	288	000	(95%	UI:	71	880-	424	640),	
or	 65%,	 by	2030.	DC	 cases	 are	 forecasted	 to	 decrease	75%	 from	






3.2 | WHO targets (Italy Polaris Model)
In	 order	 to	 achieve	 the	 WHO	 GHSS	 targets,	 treatment	 was	 ex-
panded	to	38	000	patients	annually	by	2025;	restrictions	by	fibro-
sis	 stage	 were	 lifted,	 and	 SVR	 was	 increased	 incrementally	 over	
the	 next	 10	years	 to	 represent	 the	 higher	 efficacy	 of	 treatments	
in	coming	years	(Table	2b).	Total	HCV	viraemic	infections	and	HCV	
liver-	related	morbidity	 and	mortality	 are	 expected	 to	decline	 sub-
stantially,	by	95%,	90%	and	90%,	respectively,	by	2030	(Figure	2).
3.3 | PITER adjusted model, 40%, 60% and 80% 
linked- to- care patients
Given	 the	 40%	 linkage-	to-	care	 scenario,	 total	 viraemic	 infections	
would	decline	by	60%,	to	329	000	(95%	UI:	199	960-	365	960)	pa-
tients,	 by	 2030.	 However,	 the	 eligible	 patients	 to	 treat	 would	 be	
depleted	 by	 2025.	 Under	 the	 60%	 linkage-	to-	care	 scenario,	 the	
patients	 eligible	 for	 treatment	 would	 run	 out	 in	 2028.	 Total	 in-
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127	900-	298	100)	by	the	same	year.	Under	the	80%	linkage-	to-	care	
scenario,	total	viraemic	infections	are	forecasted	to	decline	by	80%,	
from	849	000	 infections	 to	157	000	 (95%	UI:	99	380-	196	980)	by	
2030.	 The	 pool	 of	 eligible	 patients	 to	 treat	 is	 expected	 to	 be	 de-
pleted	by	2031	(Figure	1).
In	order	to	understand	the	age	distribution	of	the	eligible	infected	














The	 model	 inputs	 that	 had	 the	 largest	 contribution	 to	 the	 uncer-
tainty	 in	 the	 Italy	Polaris	and	PITER	adjusted	models	are	shown	 in	
Figure	3A,B.	 For	 the	 Italy	 Polaris	model,	 the	 anti-	HCV	 prevalence	
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alence	 in	Western	Europe,	with	 the	peak	prevalence	 in	older	ages	
(>70	years).14-16	However,	many	studies	estimating	HCV	prevalence	
in	the	Italian	general	population	were	conducted	more	than	20	years	
ago	 and	 have	 shown	 regional	 variances.17	 The	 highest	 prevalence	
rates	have	been	 reported	 in	Southern	 Italy,	 though	many	of	 these	
earlier	studies	were	conducted	in	smaller,	more	rural	areas.	Recent	
studies	have	also	 reported	decreasing	 rates	of	HCV	prevalence	 in	
the	country.11,18,19































Low (n) 371 000 Base (n) 849 000
High (n) 
1 240 000
40% 2022 2025 2027
60% 2025 2028 —





ceed	 eligible	 patients	 (“be	 depleted”).	 —Signifies	 that	 given	 the	 “high”	
prevalence	 estimate,	 the	 treated	 patients	 will	 not	 exceed	 eligible	 pa-
tients	and	treatment	levels	can	be	maintained	through	2030.
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reported	between	20%	and	80%	of	HCV+	individuals	are	aware	of	
their	 status.11,23	 This	 uncertainty	 has	 clear	 implications	 for	 treat-
ment,	as	 the	population	 first	needs	 to	be	 identified	 in	order	 to	be	


















rates	of	 injection	drug	use,	 the	younger	cohorts	 (1988+)	are	those	























As	 seen	 in	 this	modelling	 study,	 the	 rate	 of	 treatment	 uptake	will	
decline	 unless	 screening	 and	 linking	 diagnosed	 patients	 to	 care	 is	
improved.	 In	 the	country	of	Georgia,	one	of	 the	nine	countries	on	








improvement	of	diagnosis	and	 the	 linkage	 to	care—key	 factors	 for	
achieving	the	elimination	goals.28,29




treatment	 restrictions	 exceeds	 the	 proportion	 required	 for	 treat-
ment	 when	 compared	 to	 other	 dynamic	 models.30-32	 In	 addition,	
although	the	PITER	cohort	is	considered	reasonably	representative	
of	 those	 receiving	 care	 across	 the	 country,	 the	PITER	model	 uses	
a	 disease	 stage	 distribution	 based	 on	 a	 small	 proportion	 (9145	 vs	
357	000)	 of	 diagnosed	 and	 linked-	to-	care	 patients.	 The	 true	 pro-
portion	of	the	linked-	to-	care	population	in	Italy	is	unknown.	While	
rates	of	 up	 to	80%	have	been	 reported,11	 experts	 involved	 in	 the	
analysis	have	suggested	that	40%	of	the	total	infected	population	is	
linked-	to-	care.	To	address	this	uncertainty,	we	presented	the	PITER	
analysis	 under	 three	 scenarios	 of	 40%,	 60%	 and	 80%	 linkage-	to-	
care.	 In	addition,	we	evaluated	 the	 impact	of	 this	uncertainty	and	
found	 the	 percent	 change	 in	 the	 linked-	to-	care	 population	 had	 a	
smaller	influence	on	viraemic	prevalence	in	2030	than	other	factors	






eligible	 pool	 of	 patients	 to	 be	 treated	would	 run	 out	 between	2025	
and	2028,	 leaving	a	significant	proportion	of	 infected	 individuals	un-
diagnosed	and	without	access	to	care.	Increased	case	finding	through	
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